Previous 10 | Next 10 |
Summary Halozyme made a smooth transition from a failed R&D company to a successful royalty company. Their Antares acquisition is a bid to delay ENHANZE IP expiry, although the autoinjector platform is no real replacement for ENHANZE. However, for the next few years, HALO ...
Summary The new Halozyme is well-fixed to grow revenues from multiple sources over the balance of this decade and beyond. Halozyme's effective execution of its business model substantially reduces its risk profile compared to other pharmas. Halozyme's recent acquisition of Ant...
Last week’s political and financial shenanigans in the UK coupled with unusual volatility in US equities made for challenging trading conditions, writes Ian Murphy of MurphyTrading.com. For further details see: Challenging Conditions
Halozyme to Participate in the 2022 Wells Fargo Healthcare Conference PR Newswire SAN DIEGO , Sept. 1, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley , president and chief executive o...
Halo Collective Inc. (NEO: HALO) (OTCQB: HCANF) posted mostly positive results with revenues ticking up over the quarter — illustrating the west-coast operator’s pursuit to shave losses and pay down debt. The company announced its financial results for the first ...
Halozyme Therapeutics ( NASDAQ: HALO ) has priced upsized offering of $625M of 1.00% convertible senior unsecured notes due August 15, 2028. The offering was upsized from an originally announced $500M. Initial purchasers granted an option to purchase up...
Halozyme Therapeutics, Inc. Announces Upsize and Pricing of Private Offering of $625 Million of Convertible Senior Notes due 2028 PR Newswire SAN DIEGO , Aug. 15, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company"...
Halozyme Therapeutics ( NASDAQ: HALO ) has announced a proposed offering of $500M of convertible senior notes due 2028. The notes are to be offered and sold to "qualified institutional buyers." They will accrue interest payable semi-annually in arrears and will mature on Aug...
Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2028 PR Newswire The Company plans to purchase up to $200 million worth of shares concurrently with, or shortly after, the pricing of the offering SAN ...
Halozyme Therapeutics, Inc. (HALO) Q2 2022 Earnings Conference Call August 09, 2022 04:30 PM ET Company Participants Tram Bui - Vice President, Investor Relations & Corporate Communication Helen Torley - President & Chief Executive Officer Nicole LaBrosse...
News, Short Squeeze, Breakout and More Instantly...
Halozyme Therapeutics Inc. Company Name:
HALO Stock Symbol:
NASDAQ Market:
Halozyme Therapeutics Inc. Website:
Halozyme to Report Second Quarter 2024 Financial and Operating Results PR Newswire SAN DIEGO , July 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2024 financial and operating re...
2024-07-22 03:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...